HighTide Therapeutics Inc

HighTide Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies to treat patients with chronic metabolic and liver diseases in Mainland China. Its lead drug candidate is HTD1801, which is in phase III clinical trial to treat type 2 diabetes mellitus (T2DM); in phase I clinical trial to treat gradual loss of kidney function over time; phase IIb for the treatment of pathogenetic complexity and heterogeneity; phase I to treat obesity; and phase II for the treatment of chronic cholestatic liver disease. The company is also developing HTD4010, a polypeptide drug, which is in phase I clinical trial for the treatment of alcoholic hepatitis; HTF1037 a preclinical-stage for the treatment of obesity and comorbidities; HTF1057 a preclinical-stage a drug candidate for the treatment of neurodegenerative diseases; HTD1804 that is in preclinical trial to treat obesity; and HTD1805, a multifunctional small molecule drug, which is in preclinical trial for the treatment of metabolic diseases. HighTide Therapeutics, Inc. was founded in 2011 and is headquartered in Shenzhen, China.